CRNX
NASDAQ · Pharmaceuticals
Crinetics Pharmaceuticals In
$84.95
+0.11 (+0.13%)
CRNX News4 articles
Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb
Vertex Pharmaceuticals raised its 2026 outlook after strong Q2, but non-CF drugs Casgevy and Journavx face a 53% H2 growth hurdle.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
South Korean Stocks Tumble 20% from Peak Amid Chipmaker Volatility and AI Jitters
South Korean shares dropped 20% from their peak amid chipmaker volatility and AI concerns. Crinetics Pharmaceuticals surged 98.7% on a $10 billion Vertex acquisition deal.
Vertex's $10B Cash Deal Narrows Crinetics' Merger Spread
Crinetics shares traded at $83.60 premarket, just 1.7% below Vertex's $85 cash offer, as the $10 billion deal shifts focus from biotech fundamentals to merger arbitrage.